urologytimes2d
Adoption of Emerging Delivery Systems and Future Outlook for NMIBC
An expert discusses how TAR-200 shows promise for non–muscle invasive bladder cancer (NMIBC) treatment, with medical professionals optimistic about its targeted delivery, potentially improved outcomes ...
urologytimes3d
Darren Feldman, MD, on study of 177Lu-girentuximab plus nivolumab for ccRCC
The phase 2 STARLITE 2 trial is assessing 177Lu-girentuximab plus nivolumab in advanced clear cell renal cell carcinoma. The phase 2 STARLITE 2 trial (NCT05239533) is assessing the safety and efficacy ...
urologytimes2d
Hailey Frye
Michael R. Folkert, MD, PhD, discusses real-world outcomes with spacer in prostate cancer ...
urologytimes6d
Nadofaragene firadenovec maintains safety, efficacy in real-world population
"The implication for real-world decision-making is that this drug appears to hold up to what was seen in the trial," says Mark D. Tyson II, MD, MPH. Nadofaragene firadenovec-vncg (Adstiladrin) was ...
urologytimes6d
Treatment Selection for mCRPC
Panelists discuss how patients with bone-predominant mCRPC, good performance status, adequate bone marrow function, and limited visceral disease are ideal candidates for RAD-ENZ combination therapy, ...
urologytimes6d
Clinical Perspectives on Early Use of RAD-ENZ
Panelists discuss how early implementation of RAD-ENZ combination therapy requires careful consideration of patient characteristics, disease burden, and long-term treatment planning while potentially ...
urologytimes6d
Other Investigational Drug Delivery Systems in NMIBC
Experts briefly discuss investigational mitomycin delivery systems UGN-102 and UGN-103, which are being evaluated in intermediate-risk non–muscle-invasive bladder cancer (NMIBC), and share their ...
urologytimes5d
Chad Ellimoottil, MD, highlights recent telehealth extension
“For all intents and purposes, how you've been practicing telehealth currently is exactly how you'll be able to practice it until September 30," says Chad Ellimoottil, MD, MS. Last week Congress ...
urologytimes7d
Jason Hafron, MD, predicts coming advancements in bladder cancer
“[There’s] a lot going on in bladder cancer in the non–muscle invasive, muscle-invasive space, as well as in some of the biomarkers, which is exciting and will definitely have a huge impact on the ...
urologytimes7d
John P. Mulhall, MD, shares his reaction to the FDA’s testosterone labeling changes
“In 5200 men, very clearly, definitively, irrefutably, it has been shown that testosterone therapy is not associated with MACE over the course of the 12 to 24 months after commencement of testosterone ...
urologytimes4d
Perry Xu, MD
Michael R. Folkert, MD, PhD, discusses real-world outcomes with spacer in prostate cancer ...
urologytimes6d
Cretostimogene Grenadenorepvec and Integration of Novel Therapies in High-Risk BCG-Unresponsive NMIBC
Cretostimogene grenadenorepvec is an investigational targeted immunotherapy that is delivered intravesically. Can you share high-level results with from it?